ubmslateOT-logo-ubm

OT mobile menu

Search form

Topics:

Home

Are Some Cancer Drugs Costing Too Much for Too Little?

The cost of progression-free survival. Image © ALIENFORCE/Shutterstock.com 

Recent Content

A new German multicenter study is suggesting that lutetium-177 (Lu-177)-labeled PSMA-617 may be a promising new therapeutic agent for radioligand therapy in men with metastatic castration-resistant prostate cancer.

A new study is suggesting it may be possible to shut down the circuits that drive the high tumorigenicity of prostate cancer cells leading to castration-resistant prostate cancer.

A study recently published is suggesting that a key drug target, CDK4/6, regulates a cancer metastasis protein, and may play a role in combating metastasis in triple-negative breast cancer. In addition, this new finding may point to a new way of preventing metastasis in other cancers.

A 47-year-old man presents with a lesion in the parotid gland. After further assessment, a biopsy is performed. What is your diagnosis?

We spoke with Dr. Mikkael Sekeres on the difficulty of cancer patients meeting eligibility criteria for clinical trials.

Among active or former smokers undergoing lung cancer screening, longer peripheral leukocyte telomere length is associated with an increased risk of lung cancer.

An anti-HER2 dendritic vaccination may be a safe and immunogenic treatment to induce tumor-specific T-cell responses in HER2-positive, early-stage breast cancer patients.

By clicking Accept, you agree to become a member of the UBM Medica Community.